Casey Ta

Casey Ta

Auto-generated profile, based on publicly available information

Casey Ta

Department of Biomedical Informatics, Columbia University , New York, NY 10032

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
CLCong Liu
Cong Liu
JLJunghwan Lee
Junghwan Lee
CTCasey Ta
Casey Ta
ASAli Soroush
Ali Soroush
JRJames R Rogers
James R Rogers
CWChunhua Weng
Chunhua Weng
Background: COVID-19 messenger RNA (mRNA) vaccines have demonstrated efficacy and effectiveness in preventing symptomatic COVID-19, while being relatively safe in trial studies. However, vaccine breakthrough infections have been reported. Objective: This study aims to identify risk factors associated with COVID-19 breakthrough infections among fully mRNA-vaccinated individuals. Methods: We conducted a series of observational retrospective analyses using the electronic health records (EHRs) of the Columbia University Irving Medical Center/New York Presbyterian (CUIMC/NYP) up to September 21, 2021. New York City (NYC) adult residences with at least 1 polymerase chain reaction (PCR) record were included in this analysis. Poisson regression was performed to assess the association between the breakthrough infection rate in vaccinated individuals and multiple risk factors—including vaccine brand, demographics, and underlying conditions—while adjusting for calendar month, prior number of visits, and observational days in the EHR. Results: The overall estimated breakthrough infection rate was 0.16 (95% CI 0.14-0.18). Individuals who were vaccinated with Pfizer/BNT162b2 (incidence rate ratio [IRR] against Moderna/mRNA-1273=1.66, 95% CI 1.17-2.35) were male (IRR against female=1.47, 95% CI 1.11-1.94) and had compromised immune systems (IRR=1.48, 95% CI 1.09-2.00) were at the highest risk for breakthrough infections. Among all underlying conditions, those with primary immunodeficiency, a history of organ transplant, an active tumor, use of immunosuppressant medications, or Alzheimer disease were at the highest risk. Conclusions: Although we found both mRNA vaccines were effective, Moderna/mRNA-1273 had a lower incidence rate of breakthrough infections. Immunocompromised and male individuals were among the highest risk groups experiencing breakthrough infections. Given the rapidly changing nature of the SARS-CoV-2 pandemic, continued monitoring and a generalizable analysis pipeline are warranted to inform quick updates on vaccine effectiveness in real time.

15 March 2023 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
PDF file
TKTian Kang
Tian Kang
YSYingcheng Sun
Yingcheng Sun
JKJae Hyun Kim
Jae Hyun Kim
CTCasey Ta
Casey Ta
APAdler Perotte
Adler Perotte
CWChunhua Weng
Chunhua Weng
To develop a computable representation for medical evidence and to contribute a gold standard dataset of annotated randomized controlled trial (RCT) abstracts, along with a natural language processing (NLP) pipeline for transforming free-text RCT evidence in PubMed into the structured representation. Our representation, EvidenceMap, consists of 3 levels of abstraction: Medical Evidence Entity, Proposition and Map, to represent the hierarchical structure of medical evidence composition. Randomly selected RCT abstracts were annotated following EvidenceMap based on the consensus of 2 independent annotators to train an NLP pipeline. Via a user study, we measured how the EvidenceMap improved evidence comprehension and analyzed its representative capacity by comparing the evidence annotation with EvidenceMap representation and without following any specific guidelines. Two corpora including 229 disease-agnostic and 80 COVID-19 RCT abstracts were annotated, yielding 12 725 entities and 1602 propositions. EvidenceMap saves users 51.9% of the time compared to reading raw-text abstracts. Most evidence elements identified during the freeform annotation were successfully represented by EvidenceMap, and users gave the enrollment, study design, and study Results sections mean 5-scale Likert ratings of 4.85, 4.70, and 4.20, respectively. The end-to-end evaluations of the pipeline show that the evidence proposition formulation achieves F1 scores of 0.84 and 0.86 in the adjusted random index score. EvidenceMap extends the participant, intervention, comparator, and outcome framework into 3 levels of abstraction for transforming free-text evidence from the clinical literature into a computable structure. It can be used as an interoperable format for better evidence retrieval and synthesis and an interpretable representation to efficiently comprehend RCT findings.

9 July 2025 in Clinical and Translational Science
Verified
Journal Article
Open access
KFKaramarie Fecho
Karamarie Fecho
GGGwênlyn Glusman
Gwênlyn Glusman
SBSergio Baranzini
Sergio Baranzini
CBChris Bizon
Chris Bizon
MBMatthew Brush
Matthew Brush
BCBiomedical Data Translator Consortium
Biomedical Data Translator Consortium
The growing availability of biomedical data offers vast potential to improve human health, but the complexity and lack of integration of these datasets often limit their utility. To address this, the Biomedical Data Translator Consortium has developed an open‐source knowledge graph–based system—Translator—designed to integrate, harmonize, and make inferences over diverse biomedical data sources. We announce here Translator's initial public release and provide an overview of its architecture, standards, user interface, and core features. Translator employs a scalable, federated, knowledge graph framework for the integration of clinical, genomic, pharmacological, and other biomedical knowledge sources, enabling query retrieval, inference, and hypothesis generation. Translator's user interface is designed to support the exploration of knowledge relationships and the generation of insights, without requiring deep technical expertise and gradually revealing more detailed evidence, provenance, and confidence information, as needed by a given user. To demonstrate Translator's application and impact, we highlight features of the user interface in the context of three real‐world use cases: suggesting potential therapeutics for patients with rare disease; explaining the mechanism of action of a pipeline drug; and screening and validating drug candidates in a model organism. We discuss strengths and limitations of reasoning within a largely federated system and the need for rich concept modeling and deep provenance tracking. Finally, we outline future directions for enhancing Translator's functionality and expanding its data sources. Translator represents a significant step forward in making complex biomedical knowledge more accessible and actionable, aiming to accelerate translational research and improve patient care.

21 November 2024 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
FCFangyi Chen
Fangyi Chen
PAPriyanka Ahimaz
Priyanka Ahimaz
QNQuan M. Nguyen
Quan M. Nguyen
RLRachel Lewis
Rachel Lewis
WCWendy K. Chung
Wendy K. Chung
CLCong Liu
Cong Liu
Patients with rare diseases often experience prolonged diagnostic delays. Ordering appropriate genetic tests is crucial yet challenging, especially for general pediatricians without genetic expertise. Recent American College of Medical Genetics (ACMG) guidelines embrace early use of exome sequencing (ES) or genome sequencing (GS) for conditions like congenital anomalies or developmental delays while still recommend gene panels for patients exhibiting strong manifestations of a specific disease. Recognizing the difficulty in navigating these options, we developed a machine learning model trained on 1005 patient records from Columbia University Irving Medical Center to recommend appropriate genetic tests based on the phenotype information. The model achieved a remarkable performance with an AUROC of 0.823 and AUPRC of 0.918, aligning closely with decisions made by genetic specialists, and demonstrated strong generalizability (AUROC:0.77, AUPRC: 0.816) in an external cohort, indicating its potential value for general pediatricians to expedite rare disease diagnosis by enhancing genetic test ordering.

18 October 2022 in Journal of the American Medical Informatics Association
Verified
Journal Article
Open access
PDF file
CTCasey N Ta
Casey N Ta
JZJason Zucker
Jason Zucker
PCPo-Hsiang Chiu
Po-Hsiang Chiu
YFYilu Fang
Yilu Fang
KNKarthik Natarajan
Karthik Natarajan
CWChunhua Weng
Chunhua Weng
Objective: To identify and characterize clinical subgroups of hospitalized Coronavirus Disease 2019 (COVID-19) patients. Materials and Methods: Electronic health records of hospitalized COVID-19 patients at NewYork-Presbyterian/Columbia University Irving Medical Center were temporally sequenced and transformed into patient vector representations using Paragraph Vector models. K-means clustering was performed to identify subgroups. Results: A diverse cohort of 11 313 patients with COVID-19 and hospitalizations between March 2, 2020 and December 1, 2021 were identified; median [IQR] age: 61.2 [40.3–74.3]; 51.5% female. Twenty subgroups of hospitalized COVID-19 patients, labeled by increasing severity, were characterized by their demographics, conditions, outcomes, and severity (mild-moderate/severe/critical). Subgroup temporal patterns were characterized by the durations in each subgroup, transitions between subgroups, and the complete paths throughout the course of hospitalization. Discussion: Several subgroups had mild-moderate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections but were hospitalized for underlying conditions (pregnancy, cardiovascular disease [CVD], etc.). Subgroup 7 included solid organ transplant recipients who mostly developed mild-moderate or severe disease. Subgroup 9 had a history of type-2 diabetes, kidney and CVD, and suffered the highest rates of heart failure (45.2%) and end-stage renal disease (80.6%). Subgroup 13 was the oldest (median: 82.7 years) and had mixed severity but high mortality (33.3%). Subgroup 17 had critical disease and the highest mortality (64.6%), with age (median: 68.1 years) being the only notable risk factor. Subgroups 18–20 had critical disease with high complication rates and long hospitalizations (median: 40+ days). All subgroups are detailed in the full text. A chord diagram depicts the most common transitions, and paths with the highest prevalence, longest hospitalizations, lowest and highest mortalities are presented. Understanding these subgroups and their pathways may aid clinicians in their decisions for better management and earlier intervention for patients.

9 November 2024 in Journal of the American Medical Informatics Association
Verified
Journal Article
Closed access
PDF file
BIBetina Idnay
Betina Idnay
GZGongbo Zhang
Gongbo Zhang
FCFangyi Chen
Fangyi Chen
CTCasey N Ta
Casey N Ta
MSMatthew W Schelke
Matthew W Schelke
CWChunhua Weng
Chunhua Weng
Objective: This study aims to automate the prediction of Mini-Mental State Examination (MMSE) scores, a widely adopted standard for cognitive assessment in patients with Alzheimer’s disease, using natural language processing (NLP) and machine learning (ML) on structured and unstructured EHR data. Materials and Methods: We extracted demographic data, diagnoses, medications, and unstructured clinical visit notes from the EHRs. We used Latent Dirichlet Allocation (LDA) for topic modeling and Term-Frequency Inverse Document Frequency (TF-IDF) for n-grams. In addition, we extracted meta-features such as age, ethnicity, and race. Model training and evaluation employed eXtreme Gradient Boosting (XGBoost), Stochastic Gradient Descent Regressor (SGDRegressor), and Multi-Layer Perceptron (MLP). Results: We analyzed 1654 clinical visit notes collected between September 2019 and June 2023 for 1000 Alzheimer’s disease patients. The average MMSE score was 20, with patients averaging 76.4 years old, 54.7% female, and 54.7% identifying as White. The best-performing model (ie, lowest root mean squared error (RMSE)) is MLP, which achieved an RMSE of 5.53 on the validation set using n-grams, indicating superior prediction performance over other models and feature sets. The RMSE on the test set was 5.85. Discussion: This study developed a ML method to predict MMSE scores from unstructured clinical notes, demonstrating the feasibility of utilizing NLP to support cognitive assessment. Future work should focus on refining the model and evaluating its clinical relevance across diverse settings. Conclusion: We contributed a model for automating MMSE estimation using EHR features, potentially transforming cognitive assessment for Alzheimer’s patients and paving the way for more informed clinical decisions and cohort identification.